Current Report Filing (8-k)
July 06 2017 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 5, 2017
CONATUS PHARMACEUTICALS INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware
|
|
001-36003
|
|
20-3183915
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
16745 West Bernardo Drive, Suite 200
San Diego, CA
|
|
9
2127
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (858) 376-2600
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR
§240.12b-2).
Emerging growth company
x
If an emerging growth company, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
x
On July 5, 2017, the exclusive license granted by Conatus Pharmaceuticals
Inc. (“Conatus”) to Novartis Pharma AG (“Novartis”) for the global development and commercialization of
emricasan became effective under terms of the Option, Collaboration and License Agreement dated December 19, 2016 (the “Collaboration
Agreement”). The license became effective upon Conatus’ receipt of a $7 million option exercise payment from Novartis
pursuant to the Collaboration Agreement, following U.S. Federal Trade Commission review and expiration of the waiting period under
the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to the Collaboration Agreement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 6, 2017
|
|
CONATUS PHARMACEUTICALS INC.
|
|
|
|
|
|
By:
|
|
/s/ Steven J. Mento, Ph.D.
|
|
|
Name:
|
|
Steven J. Mento, Ph.D.
|
|
|
Title:
|
|
President and Chief Executive Officer
|
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Apr 2023 to Apr 2024